Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft

Journal of Pharmaceutical and Biomedical Analysis

Volumn 134, Issue , 2017, Pages 11-17

  Pourrajab, Fatemeh ^a   Torkian Velashani, Fereshteh ^a   Khanaghaei, Masoud ^a   Hekmatimoghaddam, Seyedhossein ^a   Rahaie, Mahdi ^b   Zare Khormizi, Mohamad Reza ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Cardiac biomarkers; MicroRNAs; Off pump coronary artery bypass surgery

Indexed keywords

CARDIAC TROPONIN I; CREATINE KINASE; MICRORNA; MICRORNA 126; MICRORNA 155; MICRORNA 499; TROPONIN I; UNCLASSIFIED DRUG; URIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD LEVEL; FEMALE; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; OFF PUMP CORONARY SURGERY; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVASCULARIZATION; AGED; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; TRENDS;

ADULT; AGED; BIOMARKERS; CORONARY ARTERY BYPASS, OFF-PUMP; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYOCARDIAL INFARCTION; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84995757408     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.11.014     Document Type: Article

References (30)

1. [1] Ren, J., Zhang, J., Xu, N., Han, G., Geng, Q., Song, J., Li, S., Zhao, J., Chen, H., Signature of circulating MicroRNAs as potential biomarkers in vulnerable Coronary artery disease. Plos One, 8, 2013, e80738.
2. [2] Boer, H.C., Solingen, C., Prins, J., Duijs, J.M.G.J., Huisman, M.V., Rabelink, T.J., Zonneveld, A.J., Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Euro. Heart J. 34 (2013), 3451–3457.
3. [3] Wei, Y., Nazari-Jahantigh, M., Neth, P., Weber, C., Schober, A., MicroRNA-126, −145, and −155 A therapeutic triad in atherosclerosis?. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 449–454.
4. [4] Sun, H.X., Zeng, D.Y., Li, R.T., Pang, R.P., Yang, H., Hu, Y.L., Zhang, Q., Jiang, Y., Huang, L.Y., Tang, Y.B., Yan, G.J., Zhou, J.G., Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 60 (2012), 1407–1414.
5. [5] Yao, Y., Du, J., Cao, X., Wang, Y., Huang, Y., Hu, S., Zheng, Z., Plasma levels of microRNA-499 provide an early indication of perioperative myocardial infarction in Coronary artery bypass graft patients. Plos One, 9, 2014, e104618.
6. [6] Berezin, A., Zulli, A., Kerrigan, S., Petrovic, D., Kruzliak, P., Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases. Clin. Biochem. 48 (2015), 562–568.
7. [7] Barry, O.P., Pratico, D., Savani, R.C., Gerald, G.A.F., Modulation of monocyte–endothelial cell interactions by platelet microparticles. J. Clin. Invest. 102 (1998), 136–144.
8. [8] Sun, X., Zhang, M., Sanagawa, A., Mori, C., Ito, S., Iwaki, S., Satoh, H., Fujii, S., Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb. J. 10 (2012), 1–5.
9. [9] Fukushima, Y., Nakanishi, M., Nonogi, H., Goto, Y., Iwai, N., Assessment of plasma miRNAs in congestive heart failure. Circ. J. 75 (2011), 336–340.
10. [10] Corsten, M.F., Dennert, R., Jochems, S., Kuznetsova, T., Devaux, Y., Hofstra, L., Wagner, D.R., Staessen, J.A., Heymans, S., Schroen, B., Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 3 (2010), 499–506.
11. [11] Gerald, W., Dorn, I.I., Scot, J., Matkovich, Epitranscriptional regulation of cardiovascular development and disease. J. Physiol. 593:8 (2015), 1799–1808.
12. [12] Kontaraki, J.E., Marketou, M.E., Zacharis, E.A., Parthenakis, F.I., Vardas, P.E., MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. J. Am. Soc. Hypertens. 8 (2014), 368–375.
13. [13] Shankar, A., Klein, B.E.K., Nieto, F.J., Klein, R., Association between serum uric acid level and peripheral arterial disease. Atherosclerosis 196 (2008), 749–755.
14. [14] Nazari-Jahantigh, M., Egea, V., Schober, A., Weber, C., MicroRNA-specific regulatory mechanisms in atherosclerosis. J. Mol. Cell. Cardiol.(December 89), 2016, 35–41, 10.1016/j.yjmcc.2014.10.021.
15. [15] Nie, X., Su, L., Zhou, Y., Zhao, Y., Shi, D., Liu, Y., Zhou, Z., Zhou, Y., Association between plasma levels of microRNA-126 and coronary collaterals in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi 42 (2014), 561–565.
16. [16] Hillis, G.S., Cuthbertson, B.H., Gibson, P.H., Mcneilly, J.D., Maclennan, G.S., Jeffrey, R.R., Buchan, K.G., El-Shafei, H., Gibson, G., Croal, B.L., Uric acid levels and outcome from coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 138 (2009), 200–205.
17. [17] Brodov, Y., Behar, S., Goldenberg, I., Boyko, V., Chouraqui, P., Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with Coronary artery disease [Bezafibrate infarction prevention [BIP] study]. Am. J. Cardiol. 104 (2009), 194–198.
18. [18] Pourrajab, F., Sharifi, M., Hekmatimoghaddam, S., Khanaghaei, M., Rahaie, M., Elevated levels of miR-499 protects ischemic myocardium against uric acid in patients undergoing off-pump CABG. Cor Vasa, 2016, 10.1016/j.crvasa.2016.01.002.
19. [19] Perticone, F., Maio, R., Tassone, J.E., Perticone, M., Pascale, A., Sciacqua, A., Sesti, G., Interaction between uric acid and endothelial dysfunction predicts new onset of diabetes in hypertensive patients. Int. J. Cardiol. 167 (2013), 232–236.
20. [20] Park, J.H., Jin, Y.M., Hwang, S., Cho, D.H., Kang, D.H., Jo, I., Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: a mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide 32 (2013), 36–42.
21. [21] Jin, H.M., Kim, T.J., Choi, J.H., Kim, M.J., Cho, Y.N., Nam, K.I., Kee, S.J., Moon, J.B., Choi, S.Y., Park, D.J., Lee, S.S., Park, Y.W., MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis. Res. Ther., 16, 2014, R88.
22. [22] Solingen, C., Boer, H.C., Bijkerk, R., Monge, M., Oeveren-Rietdijk, A., Seghers, L., de Vries, M.R., van der Veer, E.P., Quax, P.H., Rabelink, T.J., van Zonneveld, A.J., MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-11/Lin2 progenitor cells in ischaemia. Cardiovasc. Res. 92 (2011), 449–455.
23. [23] Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., Shah, A., Willeit, J., Mayr, M., Plasma MicroRNA profiling reveals loss of endothelial miR-126 and other MicroRNAs in type 2 diabetes. Circ. Res. 107 (2010), 810–817.
24. [24] Asgeirsdóttir, S.A., van Solingen, C., Kurniati, N.F., Zwiers, P.J., Heeringa, P., van Meurs, M., Satchell, S.C., Saleem, M.A., Mathieson, P.W., Banas, B., Kamps, J.A., Rabelink, T.J., van Zonneveld, A.J., Molema, G., MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am. J. Physiol. Renal. Physiol. 302 (2012), F1630–F1639.
25. [25] Peivandi, A.A., Dahm, M., Opfermann, U.T., Peetz, D., Doerr, F., Loos, A., Oelert, H., Comparison of cardiac troponin I versus t and creatine kinase MB after Coronary artery bypass grafting in patients with and without perioperative myocardial infarction. Herz 29 (2004), 658–664.
26. [26] Gidlof, O., Smith, J.G., Miyazu, K., Gilje, P., Spencer, A., Blomquist, S., Erlinge, D., Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc. Disor. 13 (2013), 1–9.
27. [27] Oberbach, A., Neuhaus, J., Jehmlich, N., Schlichting, N., Heinrich, M., Kullnick, Y., Mohr, F.W., Kugler, J., Baumann, S., Volker, U., Adams, V., A global proteome approach in uric acid stimulated human aortic endothelial cells revealed regulation of multiple major cellular pathways. Int. J. Cardiol. 176 (2014), 746–752.
28. [28] Hong, Q., Qi, K., Feng, Z., Huang, Z., Cui, S., Wang, L., Fu, B., Ding, R., Yang, J., Chen, X., Wu, D., Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. Cell Calcium 51 (2012), 402–410.
29. [29] Singh, U., Devaraj, S., Vasquez-Vivar, J., Jialal, I., C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J. Mol. Cell. Cardiol. 43 (2007), 780–791.
30. [30] Heina, T., Singhb, U., Vasquez-Vivar, J., Devaraj, S., Kuod, L., Jialal, I., Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 206 (2009), 61–68.